Paion AG (DB: PA8K)
Health Care · Biotechnology · DE
€0.05
+4.55% today · +400.0% 1Y
Paion AG (DB: PA8K) operates in the Biotechnology industry within the Health Care sector. The company is valued at $383.08K and employs 64 people.
Over the last twelve months the share price has gained 400.0%, trading between 0.01 and 0.23.
Tweenvest scores Paion AG across four factors: quality 41/100, value 50/100, growth 100/100. Its strongest factor is growth.
PA8K price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $383.08K
- Revenue (TTM)
- $16.17M
- P/E
- —
- EPS
- -2.79
- Dividend yield
- —
- Beta (5Y)
- 4.14
- 52-week high
- €0.23
- 52-week low
- €0.01
- Avg volume (3M)
- —
- Shares outstanding
- 7.13M
- Employees
- 64
- Next earnings
- —
About Paion AG
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
- ISIN
- DE000A3E5EG5
- Founded
- 2000
- Listed since
- Nov 10, 2022
- Exchange
- Deutsche Boerse AG
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.